Stock Events

Stock Events

Novo Nordisk 

€184.20
20523
-€1.50-0.81% Tuesday 19:36

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
40.06
Dividend Yield
0.86%
Dividend
1.58

Upcoming

Dividends

0.86%Dividend Yield
Aug 26
€0.50
Mar 26
€1.06
Aug 25
€0.50
Apr 25
€1.06
Aug 24
€0.47
10Y Growth
11.22%
5Y Growth
19.78%
3Y Growth
20.82%
1Y Growth
5.08%

Earnings

4NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
0.71
0.81
0.92
1.02
Expected EPS
0.7579867658
Actual EPS
N/A

Financials

31.38%Profit Margin
Profitable
2017
2018
2019
2020
2021
2022
23.78BRevenue
7.46BNet Income

Analyst Ratings

$30.35Average Price Target
The highest estimate is 30.35.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
0%
Sell
100%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap102.48B
Sanofi competes directly with Novo Nordisk in the diabetes and insulin markets, offering similar products and therapies.
Lilly(Eli) &
LLY
Mkt Cap994.49B
Eli Lilly is a major competitor in the diabetes care market, particularly in insulin and GLP-1 receptor agonists, directly competing with Novo Nordisk's portfolio.
Astrazeneca
AZN
Mkt Cap248.41B
AstraZeneca competes in the diabetes sector with its range of type 2 diabetes medications, posing competition to Novo Nordisk's diabetes care products.
Merck
MRK
Mkt Cap355.1B
Merck is a competitor in the diabetes market with its drug Januvia among others, competing with Novo Nordisk's diabetes management products.
Bristol-Myers Squibb
BMY
Mkt Cap130B
Bristol Myers Squibb competes in the area of diabetes and cardiovascular diseases, areas where Novo Nordisk also has a significant presence.
Pfizer
PFE
Mkt Cap157.99B
Pfizer competes with Novo Nordisk in various therapeutic areas, including chronic diseases, though not as directly in diabetes.
Novartis
NVS
Mkt Cap260.7B
Novartis competes across a broad range of therapeutic areas including cardiovascular, which overlaps with Novo Nordisk's interests.
Johnson & Johnson
JNJ
Mkt Cap640.02B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in several areas including diabetes care.
Abbott Laboratories
ABT
Mkt Cap176.41B
Abbott Laboratories competes with Novo Nordisk in the broader healthcare market, including diabetes management through its glucose monitoring devices.
Thermo Fisher Scientific
TMO
Mkt Cap225.48B
Thermo Fisher Scientific competes indirectly by providing instruments and reagents for diabetes research, affecting the market landscape.

About

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Show more...
CEO
Mr. Lars Fruergaard Jorgensen
Employees
50816
Country
Denmark
ISIN
DK0060534915
WKN
000A1XA8R

Listings

WA
PL
NVO.WA
MX
MX
NOVOBN.MX
LSE
GB
0TDD.LSE
MU
DE
NOVA.MU

0 Comments

Share your thoughts

FAQ

What is Novo Nordisk stock price today?▼
The current price of NOVC.F is €184.20 EUR — it has decreased by -0.81% in the past 24 hours. Watch Novo Nordisk stock price performance more closely on the chart.
What is Novo Nordisk stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Novo Nordisk stocks are traded under the ticker NOVC.F.
What is Novo Nordisk revenue for the last year?▼
Novo Nordisk revenue for the last year amounts to 23.78B EUR.
What is Novo Nordisk net income for the last year?▼
NOVC.F net income for the last year is 7.46B EUR.
Does Novo Nordisk pay dividends?▼
Yes, NOVC.F dividends are paid semi-annual. The last dividend per share was 0.5 . As of today, Dividend Yield (FWD)% is 0.86%.
How many employees does Novo Nordisk have?▼
As of September 18, 2026, the company has 50,816 employees.
In which sector is Novo Nordisk located?▼
Novo Nordisk operates in the Health & Wellness sector.
When did Novo Nordisk complete a stock split?▼
Novo Nordisk has not had any recent stock splits.
Where is Novo Nordisk headquartered?▼
Novo Nordisk is headquartered in Bagsvaerd, Denmark.